Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02681510 · ClinicalTrials.gov registry record · Phase 4
UW-CTRI Triple Medication Smoking Cessation Study
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT02681510 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 36 participants.
The verdict
NCT02681510, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study will focus on enhancing future smoking cessation treatment effectiveness by piloting a potentially more powerful combination of three FDA-approved pharmacotherapies: varenicline plus combination of two types of nicotine replacement therapy (NRT) treatment (nicotine lozenge and nicotine patch). Data from this pilot study will help inform the design of future studies that would use this combination treatment as a cessation tool within the chronic care arsenal of treatments.
Interventions
- DRUG Varenicline
- DRUG Nicotine Transdermal Patch
- DRUG Nicotine Mini
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-06-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02681510
The ClinicalTrials.gov registry entry for NCT02681510 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Varenicline is the first listed.
NCT02681510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02681510 about?
NCT02681510 is a clinical study titled "UW-CTRI Triple Medication Smoking Cessation Study". This study will focus on enhancing future smoking cessation treatment effectiveness by piloting a potentially more powerful combination of three FDA-approved pharmacotherapies: varenicline plus combination of two types of nicotine replacement therapy (NRT) treatment (nicotine lozenge and nicotine pa...
What is the current status of trial NCT02681510?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2016-02. Estimated completion is 2016-06-13.
What interventions are being tested in trial NCT02681510?
The interventions under investigation include: Varenicline (DRUG), Nicotine Transdermal Patch (DRUG), Nicotine Mini (DRUG).
Who is sponsoring clinical trial NCT02681510?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.